Skip to main content
Back to Current Affairs
Science & TechnologySource:

CERVAVAC: India's First Quadrivalent HPV Vaccine Receives WHO Prequalification

Wednesday, 14 October 2026
Read Original Article

Key Points

Last Updated: 14-10-2026 - CERVAVAC, India's first quadrivalent HPV vaccine, has received WHO prequalification, marking a significant milestone in global vaccine eligibility and India's vaccine development prowess. This development is crucial for UPSC aspirants, especially for General Studies Paper 2 and 3, focusing on health and technology advancements.

Key Facts About CERVAVAC

  • CERVAVAC is India's first indigenously developed quadrivalent HPV vaccine.
  • Developed by the Serum Institute of India (SII) with support from DBT, BIRAC, the Gates Foundation, and WHO's IARC.
  • Licensed for use in both girls and boys aged 9–26 years.
  • Features a two-dose schedule for ages 9–14 and a three-dose schedule for ages 15–26.
  • Targets HPV types 6, 11, 16, and 18.
  • Received WHO prequalification on September 25, 2026.
  • Part of WHO's strategy to eliminate cervical cancer by achieving 90% HPV vaccination coverage among girls by 2030.

India's Vaccine Development and Global Health Goals

The development of CERVAVAC is a testament to India's growing capabilities in the biopharmaceutical sector, aligning with the nation's strategic goals of enhancing public health infrastructure and contributing to global health initiatives. India's efforts in vaccine development not only bolster its economic growth but also position it as a key player in global health, with the Serum Institute of India being the world's largest vaccine manufacturer by volume.

UPSC Relevance

  • GS Paper 2: Health and education policies, international organizations.
  • GS Paper 3: Science and technology developments, biotechnology.
  • Prelims: Facts about CERVAVAC, WHO prequalification, HPV types.
  • Mains: Analytical themes on public health strategies, vaccine development, and international health collaborations.

FAQ Section

  • What is CERVAVAC? CERVAVAC is India's first indigenously developed quadrivalent HPV vaccine, designed to protect against four types of HPV.
  • Why is CERVAVAC important? It represents a significant advancement in India's vaccine development, offering a gender-neutral solution to prevent HPV-related diseases.
  • What are the key features of CERVAVAC? It includes a two-dose schedule for ages 9–14 and a three-dose schedule for ages 15–26, targeting HPV types 6, 11, 16, and 18.

Detailed Coverage

  • CERVAVAC is India's first indigenously developed quadrivalent HPV vaccine.
  • Received WHO prequalification on September 25, 2026.
  • Eligible for procurement by UN agencies.
  • Developed by the Serum Institute of India (SII) with support from DBT and BIRAC.
  • Contributions from the Gates Foundation and WHO's IARC.
  • Licensed for use in girls and boys aged 9–26 years.
  • Features a two-dose schedule for ages 9–14.
  • Features a three-dose schedule for ages 15–26.
  • Targets four HPV types: 6, 11, 16, and 18.
  • Types 16 and 18 are associated with cervical and other cancers.
  • Types 6 and 11 primarily cause genital warts.
  • WHO prequalification confirms standards of quality, safety, and efficacy.
  • Not equivalent to marketing authorization or national regulatory approval.
  • India's HPV vaccination program launched on February 28, 2026.
  • Over 80 lakh HPV vaccine doses administered as of September 2026.
  • CERVAVAC supports WHO's cervical cancer elimination strategy by 2030.
Science & Technology

Practice Questions

Test your understanding of this article

Question 1 of 50 / 5 answered
1

In the context of WHO's cervical cancer elimination strategy, which of the following outcomes would best reflect the successful implementation of CERVAVAC in India by 2030?